BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 6584087)

  • 1. [Evaluation of CA 19-9 radioimmunoassay].
    Toya D; Takemori Y; Kidani H; Yoneshima M; Hattori N; Sawabu N
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):509-14. PubMed ID: 6584087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of CA 15-3 radioimmunoassay].
    Takemori Y; Odani H; Watanabe H; Ohta H; Satomura Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):114-8. PubMed ID: 3467654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CA 19-9 enzyme immunoassay].
    Ota H; Odani H; Watanabe H; Satomura Y; Takemori Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
    Gan No Rinsho; 1986 Aug; 32(9):993-7. PubMed ID: 3528560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
    Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A radioimmunometric assay for circulating tumor-associated glycoprotein (TAG-72) using the antigen determinant CA 72-4].
    Ohuchi N; Takahashi K; Matoba N; Mori S
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2761-6. PubMed ID: 2458074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum determination of CA 19-9 in patients with digestive cancers and its diagnostic evaluation].
    Arakawa Y; Kobayashi H; Ozaki T; Ariga H; Matsuo Y; Honda T; Arai T; Kurosu Y; Morita K; Konuma H
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):917-25. PubMed ID: 6586110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Carbohydrate antigen CA 19-9: value in pancreatic pathology].
    Venot J; Vincent D; Gainant A; Descottes B; Cessot F; Beck C
    Gastroenterol Clin Biol; 1986 Mar; 10(3):208-10. PubMed ID: 3460925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The carbohydrate antigenic determinant 19-9 (CA 19-9): a monoclonal antibody defined tumor marker.
    DelVillano BC; Zurawski VR
    Lab Res Methods Biol Med; 1983; 8():269-82. PubMed ID: 6196588
    [No Abstract]   [Full Text] [Related]  

  • 9. [Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers].
    Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2085-93. PubMed ID: 1417016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
    Ohkura H; Sakawaki T
    Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical investigation of carbohydrate antigen CA-50].
    Ishii M; Abe O; Okura H; Okazaki N; Kawai T; Saito Y; Sawabu N; Takamizawa Y; Takeuchi T; Niitani H
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2548-55. PubMed ID: 3304170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fundamental and clinical evaluation of immunoradiometric assay (IRMA) for serum pancreatic oncofetal antigen (POA)].
    Ohba N; Hashimoto T; Nishibu M; Kashiwaya Y; Kawai K; Matsubara F; Miyazaki I
    Rinsho Byori; 1989 Feb; 37(2):153-8. PubMed ID: 2733181
    [No Abstract]   [Full Text] [Related]  

  • 13. [Preparation and evaluation of a time-resolved fluoroimmunoassay kit for CA50 determination].
    Hang JF; Wu YS; Xu WW; Yu WH; Huang Y; Li M
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):189-92. PubMed ID: 17649634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
    Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H; Teshima K; Noda K
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A basic and clinical study of CA 19-9-MP-Mitsui kit for determination of CA 19-9].
    Ishii M; Iida M; Seino Y
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2779-86. PubMed ID: 7993114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Basic and clinical evaluation of CA 130 RIA kit (D-7111) using two newly developed monoclonal antibodies; comparison with CA 125 kit].
    Saga T; Endo K; Nakashima T; Nakajima K; Matsuoka Y; Koizumi M; Kawamura Y; Watanabe Y; Hato A; Kunimatsu M
    Kaku Igaku; 1988 Oct; 25(10):1163-70. PubMed ID: 3221514
    [No Abstract]   [Full Text] [Related]  

  • 19. [The diagnostic information value of determining tumor-associated antigen Ca-19-9 in pancreatic cancer].
    Samoĭlenko VM; Afrikian MN; Itin AB
    Vopr Onkol; 1989; 35(9):1050-3. PubMed ID: 2815692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CA 19-9, a new tumor marker].
    Akai S
    Rinsho Byori; 1983 Dec; 31(12):1300-2. PubMed ID: 6587136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.